Vaccines: Poised To Deliver Significant Growth in Emerging Markets Citi Vaccine Seminar Pierre Morgon

Transcription

1 March 23, 2011 Vaccines: Poised To Deliver Significant Growth in Emerging Markets Citi Vaccine Seminar Pierre Morgon Vice President, Franchise & Global Marketing Operations Sanofi Pasteur London

2 Forward Looking Statements 2 This press release contains forward looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward looking statements are generally identified by the words expects, anticipates, believes, intends, estimates, plans and similar expressions. Although sanofi aventis management believes that the expectations reflected in such forwardlooking statements are reasonable, investors are cautioned that forward looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group s ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi aventis, including those listed under Risk Factors and Cautionary Statement Regarding Forward Looking Statements in sanofi aventis annual report on Form 20 F for the year ended December 31, Other than as required by applicable law, sanofiaventis does not undertake any obligation to update or revise any forward looking information or statements.

3 Vaccines Strategic Segment of Health Care 3 Most cost effective health care intervention available High degree of innovation and limited exposure to generics Improved pricing due to significant health benefits Significant unmet demand in emerging markets U.S.: 4.2m Mexico: 2.2m Largest birth cohorts in emerging markets (1) Brazil: 3.7m Western EU: 4.0m Russia: 1.6m China: 18.7m India: 25.1m One of the fastest growing markets (1) Estimated birth cohorts in millions, Census Bureau, updated November 26, 2009

4 Sanofi aventis A Unique Position in Vaccines 4 A strong heritage A broad and diversified product offering A success story based on leadership and innovation Leadership in Influenza, Meningitis and Pediatric vaccines New wave of innovation in preparation with vaccines against Dengue Fever and Clostridium Difficile FY2010 Sales % by Franchise Pandemic Influenza 12% Seasonal Influenza 22% A Global Leader in Vaccines FY2010 sales: 3,808m, +4.8% (1) JV with Merck in EU: 918m (2) 22% market share in 2010 (3) Diversified and Balanced Portfolio Other Travel & 4% Endemics 10% Polio/ Pertussis/ Hib 26% Boosters 12% Meningitis/ Pneumonia 14% (1) Growth at constant exchange rates (2) Accounted for using the equity method (3) Based on reported FY2010 results and Sanofi Pasteur internal estimates for Others Sanofi Pasteur MS estimate includes 50% of Sanofi Pasteur MSD sales, excluding pandemic sales

5 Historical Performance Driven by the U.S. and Europe Still Room to Grow 5 Highly concentrated market 4 large international players High immunization rates Opportunities remain in all age segments Differentiation as competitive advantage Further growth to come from life cycle management and innovative vaccines U.S.: Market Leader Everywhere We Compete 100% 80% 60% 40% 20% 0% Market Share by Major Franchise YTD December 2010 (1) 32% 32% 68% 68% Pediatric Pertussis 49% 51% 95% (2) Boosters Flu Meningitis Sanofi Pasteur All other competitors (1) 2010 Competitors annual earnings statements and Sanofi Pasteur internal sales data (2) Seasonal influenza Internal projections based on published CDC and manufacturer statements

6 Significant Future Growth to Be Fuelled by The Emerging Markets 6 Large population and birth cohorts Low immunization rates Projected Emerging Market (1) Vaccines Sales (2) ( bn) CAGR= 15% Economic growth driving middle class and private sector expansion Expansion of government healthcare coverage 5 10 Many unmet medical needs e 2015e (1) Emerging markets includes Asia Pacific (excluding Japan, Australia and New Zealand), Africa, Middle East, Eastern Europe and Latin America (2) Sanofi Pasteur internal estimates excluding pandemic influenza sales

7 Sanofi Pasteur Has a Well Established Presence in Emerging Markets 7 FY 2010 Sanofi Pasteur Sales in Emerging Markets Ranks #1 1,386m (1), +46.2% 1,025m, +15.4%, excluding Pandemic Influenza Latin America Sales in 2010 (1) : 601m, + 116% Africa & Middle East Sales in 2010 (1) : 226m, +16% Eastern Europe (2) Sales in 2010 (1) : 166m, +33% Asia Sales in 2010 (1) : 342m, + 21% Sales growth is at constant exchange rates (1) Including pandemic vaccine sales (2) Includes Turkey

8 Ensuring Long Term Growth Through Tailored R&D, Industrial and Commercial Footprint 8 Present in over 100 countries Investing in local manufacturing 4 international sites: China, Thailand, Argentina and India 2 sites under construction: China and Mexico Emerging Markets Industrial and R&D Presence Beijing Shenzhen Regional approaches for R&D project execution 2 main centers: China and India Shantha a strategic asset Cost effective manufacturing base Ocoyoacac Pilar Shantha GPO Thailand Offering adapted to UNICEF/GAVI segment R&D pipeline (Rotavirus, HPV) Industrial site R&D site

9 A Strong Record of Alliances To Access Emerging Markets 9 Partner of choice Selected Sanofi Pasteur Partnerships in Emerging Markets Over 14 partnerships MEFAR Chumakov Built long standing relationships New partnerships in development Birmex Butantan The Biovac Institute EPI

10 A Solid R&D Pipeline to Fuel our Growth 10 Phase I Phase II Phase III Registration Tuberculosis Recombinant subunit vaccine DTP HepB Polio Hib Pediatric hexavalentvaccine Dengue Mild to severe dengue fever vaccine Fluzone ID Seasonal influenza vaccine Intradermal micro injection, U.S. Streptococcus pneumonia Meningitis & pneumonia vaccine Pseudomonas aeruginosa Antibody fragment product Prevention of ventilator associated pneumonia ACAM Cdiff Clostridium difficile Toxoid vaccine Rabies mab post exposure prophylaxis Hexaxim DTP HepB Polio Hib vaccine Quadracel Diphtheria, tetanus, pertussis and polio vaccine; 4 6 years of age Menactra Meningococcal conjugate vaccine Infant / Toddler 9 12 months Rotavirus Live Attenuated Tetravalent Rotavirus oral vaccine Rabies VRVg Purified vero rabies vaccine Fluzone QIV Quadrivalent inactivated influenza vaccine Meninge ACYW conj. 2 nd generation meningococcal conjugate Infant vaccine Primary Target Market Developed Emerging Developed & Emerging

11 A Broad Product Offering Well Suited for Emerging Markets Sanofi Pasteur Sales Performance in Emerging Markets (1) Sesaonal Influenza 257m, +10.9% Polio/Pertussis/Hib 384m, +11.4% Pandemic Influenza 361m Shanchol Others 15m Travel & other endemics 235m, +15.8% Meningitis/Pneumo Boosters 101m, +25.6% 33m, +32% (1) Sales growth at constant exchange rates

12 A Pediatric Combo Portfolio Tailored to Emerging Markets 12 3 combo families to address different market cluster needs 5 component acellular Pertussis 2 component acellular Pertussis Hexaxim First launches expected end of 2013 Whole cell Pertussis Unmatched capacity for Oral and Inactivated Polio Vaccines Pediatric combination includes Diphtheria, Tetanus, Pertussis, inactivated Polio, plus Haemophilus b and/or Hepatitis B depending on vaccine

13 The Broadest Seasonal Influenza Vaccines Offering of the Industry 13 Seasonal Influenza Vaccines Unique Manufacturing Platform Northern Hemisphere: ~40% MS (1) Southern Hemisphere: ~70% MS (1) 2010 net sales of 257m in Emerging Markets New differentiated offering Swiftwater Ocoyoacac Val de Reuil Shenzhen First intradermal influenza vaccine Existing sites Under Construction (1) Market shares (MS) based on reported FY2010 results and Sanofi Pasteur internal estimates for other companies (includes all countries in a given hemisphere)

14 Dengue: A Growing Health Concern 14 Mosquito borne disease 2 nd most widespread tropical disease after Malaria 2.5bn people in tropical and subtropical region; annual incidence of m cases Increasing geographic spread and burden of disease High economic burden in endemic countries No effective drug treatments No effective prevention Global Prevalence of Dengue (1) Areas infested with Aedes aegypti Areas with Aedes aegypti and dengue epidemic activity (1) Sources: WHO

15 Developing a Safe and Effective Tetravalent Vaccine against Dengue 15 Chimerivax TM technology Phase III study on going Dengue Facilities Construction Status (Neuville, France) Over 15 countries involved Around 39,000 subjects recruited including around 11,000 children Expected to be first to market Market estimated to be over 1 billion First submissions planned in 2013 Partnering Dengue Vaccine Initiative (DVI) 100m dose capacity To be online end 2013

16 Sanofi pasteur in Asia 16 China Sales of 104m in 2010 (1) Leadership position in flu Shenzhen plant construction and validation finalized Growth driven by both pediatric and adult vaccines Continuing history of first to market (Flu, Hib, Pneumo, and IPV) Launching India Sales of 48m in 2010 (1) Broad portfolio adapted to market Complementary Sanofi Pasteur/ Shantha vaccines range Strong presence in pediatric vaccines with Expanded presence and coverage OPV vaccine supplier contributing to Polio eradication IPV: Inactivated Polio vaccine (1) Including pandemic vaccine sales OPV: Oral Polio vaccine

17 in Latin America 17 Brazil Sales of 294m in 2010 (1) Flu leadership position Delivered Yellow Fever for outbreak control Introduction of new vaccines Preparing Dengue vaccine introduction into public sector Mexico Sales of 185m in 2010 (1) Flu leadership position Local production platform in construction Pediatric combo vaccine leadership Growth driven by introduction of new vaccines in the public market (1) Including pandemic vaccine sales

18 Ensuring Long term Growth in Emerging Markets 18 Broad vaccines offering adapted to local needs Strong industrial and commercial presence Key local partnerships Regional base Promising projects in development